In a session held during the Florida Society of Clinical Oncology’s annual meeting in April, panelist James Almas, MD, vice president and national medical director of clinical effectiveness at LabCorp, and previously a medical officer at CMS in the Coverage Analysis Group, announced that he expected the National Coverage Determination to be reopened for Foundation Medicine’s FDA-approved companion diagnostic. By the end of the month, CMS revealed that they had done just that.